The development of translational researchers in thyroid cancer requires a diligent commitment to the identification of talented researchers at the junior level, and the placement pf these individuals into a supportive environment which provides not only significant expertise in thyroid cancer, but also the provision for mentorship. Another way to produce leaders in the field of thyroid cancer research is to encourage successful translational scientists to re-focus their talents from other areas into this area. The Career Development Program (CDP) of this thyroid cancer SPORE is an essential component of the application because it provides the mechanism to encourage excellent junior scientists to establish careers in this field and to attract the expertise of established researchers from other disciplines. For this thyroid cancer-focused application, the combination of resources (both patient and research resources) and guidance present at The Ohio State University (OSU) and at the MD Anderson Gancer Center (MDACC) provides an unparalleled environment to enable these new and junior investigators to succeed as independent researchers and to develop future careers which will contribute to progress in stemming the rising incidence of this malignancy and develop new therapies for those with local and distant metastatic disease. To this end, the CDP will fund promising young investigators or, in certain circumstances, more senior faculty reorienting from clinical practice or another field for 2 years at $50,000 per year. Special attention will be paid to the recruitment of applicants from diverse backgrounds. Applications will be solicited from all departments and centers at OSU and MDACC. They will be screened for eligibility by CDP Leadership to assure adequate representation from qualified women and minorities. Applications will be judged based on the potential of the candidate, the strength of the proposed research and the appropriateness of the mentor. Applications will be scored and ranked by members of the CDP Committee and final funding recommendations made to the SPORE Steering Committee. Each position will be funded for one year, with a second year dependent upon satisfactory progress. Over the course of the grant, the SPORE will provide 44.6% of the funding for the CPD, which will be matched by 38.1%, and 17.3% provided from OSUCCC and MDACC, respectively. Success of the program will be judged by the quality of the science generated by the awardees, their success in obtaining external peer-reviewed funding, their success in academic advancement, and their retention in academia and translational research in thyroid cancer.

Public Health Relevance

The Career Development Program (CDP) is an important component of this thyroid cancer SPORE application and the national SPORE program because it will assure a cadre of academic faculty who are specially trained translational scientists and clinicians dedicated to discover and apply new approaches to understanding the etiology and epidemiology, prevention, diagnosis, treatment and cure of patients with thyroid cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
United States
Zip Code
Bagheri-Yarmand, Rozita; Sinha, Krishna M; Li, Ling et al. (2018) Combinations of Tyrosine Kinase Inhibitor and ERAD Inhibitor Promote Oxidative Stress-Induced Apoptosis through ATF4 and KLF9 in Medullary Thyroid Cancer. Mol Cancer Res :
Puli, Oorvashi Roy; Danysh, Brian P; McBeath, Elena et al. (2018) The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells. Neoplasia 20:1121-1134
Abrams, Zachary B; Zucker, Mark; Wang, Min et al. (2018) Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics 19:738
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
He, Huiling; Li, Wei; Liyanarachchi, Sandya et al. (2018) The Role of NRG1 in the Predisposition to Papillary Thyroid Carcinoma. J Clin Endocrinol Metab 103:1369-1379
Chakedis, Jeffery; Shirley, Lawrence A; Terando, Alicia M et al. (2018) Identification of the Thoracic Duct Using Indocyanine Green During Cervical Lymphadenectomy. Ann Surg Oncol 25:3711-3717
Xu, Congcong; Haque, Farzin; Jasinski, Daniel L et al. (2018) Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy. Cancer Lett 414:57-70
Segkos, Konstantinos; Porter, Kyle; Senter, Leigha et al. (2018) Neck Ultrasound in Patients with Follicular Thyroid Carcinoma. Horm Cancer 9:433-439
Wang, Yanqiang; He, Huiling; Liyanarachchi, Sandya et al. (2018) The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma. Genet Med 20:927-935
Valenciaga, Anisley; Saji, Motoyasu; Yu, Lianbo et al. (2018) Transcriptional targeting of oncogene addiction in medullary thyroid cancer. JCI Insight 3:

Showing the most recent 10 out of 50 publications